ESMOLOL HYDROCHLORIDE

Post-LOE

esmolol hydrochloride in sodium chloride

Viatris (2)

ANDAINJECTIONINJECTABLE

Approved

Dec 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ESMOLOL HYDROCHLORIDE (esmolol hydrochloride in sodium chloride) by Viatris (2) is 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Approved for non-compensatory sinus tachycardia where, the physician's judgment, the rapid heart rate requires specific intervention and 4 more indications. First approved in 2022.

Drug data last refreshed 1w ago

Mechanism of Action

1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes.…

Indications (6)

non-compensatory sinus tachycardia where the physician's judgment

Worked on ESMOLOL HYDROCHLORIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.